Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases

Clinical Genetics

Volumn 89, Issue 3, 2016, Pages 285-294

  Rai, K ^a   Pilarski, R ^a   Cebulla, C M ^b   Abdel Rahman, M H ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c MENOUFIA UNIVERSITY   (Egypt)

Author keywords

BAP1; Cutaneous melanoma; Germline; Mesothelioma; Renal cell carcinoma; Uveal melanoma

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

BREAST CARCINOMA; CUTANEOUS MELANOMA; DISEASE PREDISPOSITION; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HUMAN; KIDNEY CARCINOMA; LIPOSARCOMA; MALIGNANT MESOTHELIOMA; METASTASIS; NEURILEMOMA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE; UVEA MELANOMA; ADOLESCENT; ADULT; AGED; CASE REPORT; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEREDITARY TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; PEDIGREE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PEDIGREE; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84958629420     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12630     Document Type: Review

References (91)

1. ®. Baltimore, MD: Johns Hopkins University, 2014: MIM Number: 614327.
2. Abdel-Rahman MH, Pilarski R, Cebulla CM et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011: 48: 856-859.
3. Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011: 43: 1022-1025.
4. Wiesner T, Obenauf AC, Murali R et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011: 43: 1018-1021.
5. Popova T, Hebert L, Jacquemin V et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013: 92: 974-980.
6. Jensen DE, Proctor M, Marquis ST et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998: 16: 1097-1112.
7. Ventii KH, Devi NS, Friedrich KL et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008: 68: 6953-6962.
8. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 2011: 60: 3-11.
9. Eletr ZM, Yin L, Wilkinson KD. BAP1 is phosphorylated at serine 592 in S-phase following DNA damage. FEBS Lett 2013: 587: 3906-3911.
10. Yu H, Pak H, Hammond-Martel I et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA 2014: 111: 285-290.
11. Jensen DE, Rauscher FJ 3rd. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci 1999: 886: 191-194.
12. Jensen DE, Rauscher FJ 3rd. Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Cancer Lett 1999: 143 (Suppl 1): S13-S17.
13. Carbone M, Yang H, Pass H, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer 2013: 13: 153-159.
14. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology 2013: 45: 116-126.
15. White AE, Harper JW. Cancer. Emerging anatomy of the BAP1 tumor suppressor system. Science 2012: 337: 1463-1464.
16. Yu H, Mashtalir N, Daou S et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 2010: 30: 5071-5085.
17. Dey A, Seshasayee D, Noubade R et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 2012: 337: 1541-1546.
18. Pilarski R, Cebulla CM, Massengill JB et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer 2014: 53: 177-182.
19. Cebulla CM, Binkley EM, Pilarski R et al. Analysis of BAP1 germline gene mutation in young uveal melanoma patients. Ophthalmic Genet 2015: 36 (2): 126-131.
20. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015: 17: 405-423.
21. Aoude LG, Vajdic CM, Kricker A, Armstrong B, Hayward NK. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res 2013: 26: 278-279.
22. Aoude LG, Wadt K, Bojesen A et al. A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PLoS One 2013: 8: e72144.
23. Cheung M, Talarchek J, Schindeler K et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 2013: 206: 206-210.
24. de la Fouchardiere A, Cabaret O, Savin L et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet 2014. Epub 31 July 2014. doi: 10.1111/cge.12472.
25. Gupta MP, Lane AM, DeAngelis MM et al. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol 2015. Epub 14 May 2015. doi: 10.1001/jamaophthalmol.2015.1119.
26. Harbour JW, Onken MD, Roberson ED et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010: 330: 1410-1413.
27. Hoiom V, Edsgard D, Helgadottir H et al. Hereditary uveal melanoma: a report of a germline mutation in BAP1. Genes Chromosomes Cancer 2013: 52: 378-384.
28. Maerker DA, Zeschnigk M, Nelles J et al. BAP1 germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol 2014: 98: 224-227.
29. Njauw CN, Kim I, Piris A et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012: 7: e35295.
30. Wadt K, Choi J, Chung JY et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 2012: 25: 815-818.
31. Wadt KA, Aoude LG, Johansson P et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 2014. Epub 15 September 2014. doi: 10.1111/cge.12501.
32. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011: 118: 1881-1885.
33. Betti M, Casalone E, Ferrante D et al. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer 2015: 54: 51-62.
34. Ribeiro C, Campelos S, Moura CS, Machado JC, Justino A, Parente B. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation. Ann Oncol 2013: 24: 2147-2150.
35. Wiesner T, Fried I, Ulz P et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol 2012: 30: e337-e340.
36. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007: 12: 20-37.
37. Surveillance, Epidemiology, and End Results (SEER) Program. In: National Cancer Institute D, Surveillance Research Program, Surveillance Systems Branch, ed., 2013.
38. Farley MN, Schmidt LS, Mester JL et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 2013: 11: 1061-1071.
39. Gossage L, Murtaza M, Slatter AF et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014: 53: 38-51.
40. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012: 44: 751-759.
41. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004: 24: 115-125.
42. de la Fouchardiere A, Cabaret O, Petre J et al. Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome. Acta Neuropathol 2015: 129: 921-923.
43. Ostrom QT, Gittleman H, Liao P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014: 16 (Suppl 4): iv1-iv63.
44. Forbes SA, Bindal N, Bamford S et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011: 39: D945-D950.
45. Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br J Cancer 2014: 111: 1373-1380.
46. Koopmans AE, Verdijk RM, Brouwer RW et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol 2014: 27: 1321-1330.
47. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology 2013: 45: 651-656.
48. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007: 18: 985-990.
49. Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res 2014: 20: 145-151.
50. Alakus H, Yost SE, Woo B et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 2015: 13: 122.
51. Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011: 43: 668-672.
52. Nasu M, Emi M, Pastorino S et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 2015: 10: 565-576.
53. Murali R, Wilmott JS, Jakrot V et al. BAP1 expression in cutaneous melanoma: a pilot study. Pathology 2013: 45: 606-609.
54. Piris A, Mihm MC Jr, Hoang MP. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. Hum Pathol 2015: 46: 239-245.
55. Hakimi AA, Chen YB, Wren J et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013: 63: 848-854.
56. Hakimi AA, Ostrovnaya I, Reva B et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013: 19: 3259-3267.
57. Ho TH, Kapur P, Joseph RW et al. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol 2015: 33: 23 e29-14.
58. Joseph RW, Kapur P, Serie DJ et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2014: 120: 1059-1067.
59. Kapur P, Christie A, Raman JD et al. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 2014: 191: 603-610.
60. Shinagare AB, Vikram R, Jaffe C et al. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group. Abdom Imaging 2015. Epub 10 March 2015.
61. Carbone M, Ferris LK, Baumann F et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012: 10: 179.
62. Llamas-Velasco M, Perez-Gonzalez YC, Requena L, Kutzner H. Histopathologic clues for the diagnosis of Wiesner nevus. J Am Acad Dermatol 2014: 70: 549-554.
63. Wiesner T, Murali R, Fried I et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012: 36: 818-830.
64. Martorano LM, Winkelmann RR, Cebulla CM, Abdel-Rahman MH, Campbell SM. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. Int J Dermatol 2014: 53: 657-663.
65. Busam KJ, Wanna M, Wiesner T. Multiple epithelioid Spitz nevi or tumors with loss of BAP1 expression: a clue to a hereditary tumor syndrome. JAMA Dermatol 2013: 149: 335-339.
66. Busam KJ, Sung J, Wiesner T, von Deimling A, Jungbluth A. Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. Am J Surg Pathol 2013: 37: 193-199.
67. Chan-On W, Nairismagi ML, Ong CK et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013: 45: 1474-1478.
68. Churi CR, Shroff R, Wang Y et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014: 9: e115383.
69. Je EM, Lee SH, Yoo NJ. Somatic mutation of a tumor suppressor gene BAP1 is rare in breast, prostate, gastric and colorectal cancers. APMIS 2012: 120: 855-856.
70. Jhunjhunwala S, Jiang Z, Stawiski EW et al. Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol 2014: 15: 436.
71. Jiao Y, Pawlik TM, Anders RA et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013: 45: 1470-1473.
72. Luscan A, Just PA, Briand A et al. Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes. Br J Ophthalmol 2015: 99(4): 437-439.
73. Mochel MC, Piris A, Nose V, Hoang MP. Loss of BAP1 expression in basal cell carcinomas in patients with germline BAP1 mutations. Am J Clin Pathol 2015: 143: 901-904.
74. Simbolo M, Fassan M, Ruzzenente A et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 2014: 5: 2839-2852.
75. Tang J, Xi S, Wang G et al. Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol 2013: 30: 541.
76. Coupier I, Cousin PY, Hughes D et al. BAP1 and breast cancer risk. Fam Cancer 2005: 4: 273-277.
77. Guenard F, Labrie Y, Ouellette G, Beauparlant CJ, Durocher F, INHERIT BRCAs. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer. J Hum Genet 2009: 54: 152-161.
78. Karlo CA, Di Paolo PL, Chaim J et al. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 2014: 270: 464-471.
79. Kapur P, Pena-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013: 14: 159-167.
80. Kumar R, Taylor M, Miao B et al. BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol 2015: 135: 1089-1097.
81. Baumann F, Flores E, Napolitano A et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015: 36: 76-81.
82. de Reynies A, Jaurand MC, Renier A et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 2014: 20: 1323-1334.
83. Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Transl Oncol 2015: 8: 35-39.
84. Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology 2014: 121: 1281-1288.
85. Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand J Work Environ Health 2015: 41: 5-15.
86. Kefford R, Bishop JN, Tucker M et al. Genetic testing for melanoma. Lancet Oncol 2002: 3: 653-654.
87. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999: 17: 3245-3251.
88. Lonser RR, Glenn GM, Walther M et al. von Hippel-Lindau disease. Lancet 2003: 361: 2059-2067.
89. Kaya H, Demir M, Taylan M et al. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 2015: 16: 1403-1407.
90. Landreville S, Agapova OA, Matatall KA et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012: 18: 408-416.
91. Weber DG, Casjens S, Johnen G et al. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS One 2014: 9: e114483.